1
|
Gennaro G, Bucchi L, Ravaioli A, Zorzi M, Falcini F, Russo F, Caumo F. The risk-based breast screening (RIBBS) study protocol: a personalized screening model for young women. LA RADIOLOGIA MEDICA 2024; 129:727-736. [PMID: 38512619 PMCID: PMC11088554 DOI: 10.1007/s11547-024-01797-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 02/02/2024] [Indexed: 03/23/2024]
Abstract
The optimal mammography screening strategy for women aged 45-49 years is a matter of debate. We present the RIBBS study protocol, a quasi-experimental, prospective, population-based study comparing a risk- and breast density-stratified screening model (interventional cohort) with annual digital mammography (DM) screening (observational control cohort) in a real-world setting. The interventional cohort consists of 10,269 women aged 45 years enrolled between 2020 and 2021 from two provinces of the Veneto Region (northen Italy). At baseline, participants underwent two-view digital breast tomosynthesis (DBT) and completed the Tyrer-Cuzick risk prediction model. Volumetric breast density (VBD) was calculated from DBT and the lifetime risk (LTR) was estimated by including VBD among the risk factors. Based on VBD and LTR, women were classified into five subgroups with specific screening protocols for subsequent screening rounds: (1) LTR ≤ 17% and nondense breast: biennial DBT; (2) LTR ≤ 17% and dense breast: biennial DBT and ultrasound; (3) LTR 17-30% or LTR > 30% without family history of BC, and nondense breast: annual DBT; (4) LTR 17-30% or > 30% without family history of BC, and dense breast: annual DBT and ultrasound; and (5) LTR > 30% and family history of BC: annual DBT and breast MRI. The interventional cohort is still ongoing. An observational, nonequivalent control cohort of 43,000 women aged 45 years participating in an annual DM screening programme was recruited in three provinces of the neighbouring Emilia-Romagna Region. Cumulative incidence rates of advanced BC at three, five, and ten years between the two cohorts will be compared, adjusting for the incidence difference at baseline.Trial registration This study is registered on Clinicaltrials.gov (NCT05675085).
Collapse
Affiliation(s)
| | - Lauro Bucchi
- Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy.
| | - Alessandra Ravaioli
- Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy
| | - Manuel Zorzi
- SER - Servizio Epidemiologico Regionale e Registri, Azienda Zero, Padua, Italy
| | - Fabio Falcini
- Emilia-Romagna Cancer Registry, Romagna Cancer Institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì, Italy
- Cancer Prevention Unit, Local Health Authority, Forlì, Italy
| | - Francesca Russo
- Direzione Prevenzione, Sicurezza Alimentare, Veterinaria, Regione del Veneto, Venice, Italy
| | | |
Collapse
|
2
|
Zhu J, Wang L, Gong W, Li X, Wang Y, Zhu C, Li H, Shi L, Yang C, Du L. Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study. Cancer 2024; 130:1403-1414. [PMID: 37916832 DOI: 10.1002/cncr.35095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 09/06/2023] [Accepted: 09/28/2023] [Indexed: 11/03/2023]
Abstract
INTRODUCTION Breast cancer is a significant contributor to female mortality, exerting a public health burden worldwide, especially in China, where risk-prediction models with good discriminating accuracy for breast cancer are still scarce. METHODS A multicenter screening cohort study was conducted as part of the Cancer Screening Program in Urban China. Dwellers aged 40-74 years were recruited between 2014 and 2019 and prospectively followed up until June 30, 2021. The entire data set was divided by year of enrollment to develop a prediction model and validate it internally. Multivariate Cox regression was used to ascertain predictors and develop a risk-prediction model. Model performance at 1, 3, and 5 years was evaluated using the area under the curve, nomogram, and calibration curves and subsequently validated internally. The prediction model incorporates selected factors that are assigned appropriate weights to establish a risk-scoring algorithm. Guided by the risk score, participants were categorized into low-, medium-, and high-risk groups for breast cancer. The cutoff values were chosen using X-tile plots. Sensitivity analysis was conducted by categorizing breast cancer risk into the low- and high-risk groups. A decision curve analysis was used to assess the clinical utility of the model. RESULTS Of the 70,520 women enrolled, 447 were diagnosed with breast cancer (median follow-up, 6.43 [interquartile range, 3.99-7.12] years). The final prediction model included age and education level (high, hazard ratio [HR], 2.01 [95% CI, 1.31-3.09]), menopausal age (≥50 years, 1.34 [1.03-1.75]), previous benign breast disease (1.42 [1.09-1.83]), and reproductive surgery (1.28 [0.97-1.69]). The 1-year area under the curve was 0.607 in the development set and 0.643 in the validation set. Moderate predictive discrimination and satisfactory calibration were observed for the validation set. The risk predictions demonstrated statistically significant differences between the low-, medium-, and high-risk groups (p < .001). Compared with the low-risk group, women in the high- and medium-risk groups posed a 2.17-fold and 1.62-fold elevated risk of breast cancer, respectively. Similar results were obtained in the sensitivity analyses. A web-based calculator was developed to estimate risk stratification for women. CONCLUSIONS This study developed and internally validated a risk-adapted and user-friendly risk-prediction model by incorporating easily accessible variables and female factors. The personalized model demonstrated reliable calibration and moderate discriminative ability. Risk-stratified screening strategies contribute to precisely distinguishing high-risk individuals from asymptomatic individuals and prioritizing breast cancer screening. PLAIN LANGUAGE SUMMARY Breast cancer remains a burden in China. To enhance breast cancer screening, we need to incorporate population stratification in screening. Accurate risk-prediction models for breast cancer remain scarce in China. We established and validated a risk-adapted and user-friendly risk-prediction model by incorporating routinely available variables along with female factors. Using this risk-stratified model helps accurately identify high-risk individuals, which is of significant importance when considering integrating individual risk assessments into mass screening programs for breast cancer. Current clinical breast cancer screening lacks a constructive clinical pathway and guiding recommendations. Our findings can better guide clinicians and health care providers.
Collapse
Affiliation(s)
- Juan Zhu
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Le Wang
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Weiwei Gong
- Department of Chronic and Noncommunicable Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Xue Li
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Youqing Wang
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Chen Zhu
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Huizhang Li
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Lei Shi
- Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Chen Yang
- Department of Ultrasound, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
| | - Lingbin Du
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China
- School of Public Health and Management, Wenzhou Medical University, Wenzhou, Zhejiang, China
| |
Collapse
|
3
|
Gard CC, Tice JA, Miglioretti DL, Sprague BL, Bissell MC, Henderson LM, Kerlikowske K. Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. J Clin Oncol 2024; 42:779-789. [PMID: 37976443 PMCID: PMC10906584 DOI: 10.1200/jco.22.02470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 08/08/2023] [Accepted: 09/18/2023] [Indexed: 11/19/2023] Open
Abstract
PURPOSE We extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening. METHODS We used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort. We evaluated calibration using the ratio of expected-to-observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). RESULTS We analyzed data from 1,455,493 women age 35-79 years without a history of breast cancer. During a mean follow-up of 7.3 years, 30,266 women were diagnosed with invasive breast cancer. The BCSC v3 model had an E/O of 1.03 (95% CI, 1.01 to 1.04) and an AUROC of 0.646 for 5-year risk. Compared with the v2 model, discrimination of the v3 model improved most in Asian, White, and Black women. Among women with a BMI of 30.0-34.9 kg/m2, the true-positive rate in women with an estimated 5-year risk of 3% or higher increased from 10.0% (v2) to 19.8% (v3) and the improvement was greater among women with a BMI of ≥35 kg/m2 (7.6%-19.8%). CONCLUSION The BCSC v3 model updates an already well-calibrated and validated breast cancer risk assessment tool to include additional important risk factors. The inclusion of BMI was associated with the largest improvement in estimated risk for individual women.
Collapse
Affiliation(s)
- Charlotte C. Gard
- Department of Economics, Applied Statistics, and International Business, New Mexico State University, Las Cruces, NM
| | - Jeffrey A. Tice
- Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA
| | - Diana L. Miglioretti
- University of California, Davis, Davis, CA
- Kaiser Permanente Washington Health Research Institute, Seattle, WA
| | - Brian L. Sprague
- Department of Surgery, University of Vermont Cancer Center, Burlington, VT
- Department of Radiology, University of Vermont Cancer Center, Burlington, VT
| | | | | | - Karla Kerlikowske
- General Internal Medicine Section, Department of Veteran Affairs, University of California, San Francisco, San Francisco, CA
- Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
| |
Collapse
|
4
|
Yan H, Ren W, Jia M, Xue P, Li Z, Zhang S, He L, Qiao Y. Breast cancer risk factors and mammographic density among 12518 average-risk women in rural China. BMC Cancer 2023; 23:952. [PMID: 37814233 PMCID: PMC10561452 DOI: 10.1186/s12885-023-11444-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Accepted: 09/25/2023] [Indexed: 10/11/2023] Open
Abstract
BACKGROUND Mammographic density (MD) is a strong risk factor for breast cancer. We aimed to evaluate the association between MD and breast cancer related risk factors among average-risk women in rural China. METHODS This is a population-based screening study. 12518 women aged 45-64 years with complete MD data from three maternal and childcare hospitals in China were included in the final analysis. ORs and 95%CIs were estimated using generalized logit model by comparing each higher MD (BI-RADS b, c, d) to the lowest group (BI-RADS a). The cumulative logistic regression model was used to estimate the ORtrend (95%CI) and Ptrend by treating MD as an ordinal variable. RESULTS Older age (ORtrend = 0.81, 95%CI: 0.79-0.81, per 2-year increase), higher BMI (ORtrend = 0.73, 95%CI: 0.71-0.75, per 2 kg/m2), more births (ORtrend = 0.47, 95%CI: 0.41-0.54, 3 + vs. 0-1), postmenopausal status (ORtrend = 0.42, 95%CI: 0.38-0.46) were associated with lower MD. For parous women, longer duration of breastfeeding was found to be associated with higher MD when adjusting for study site, age, BMI, and age of first full-term birth (ORtrend = 1.53, 95%CI: 1.27-1.85, 25 + months vs. no breastfeeding; ORtrend = 1.45, 95%CI: 1.20-1.75, 19-24 months vs. no breastfeeding), however, the association became non-significant when adjusting all covariates. Associations between examined risk factors and MD were similar in premenopausal and postmenopausal women except for level of education and oral hormone drug usage. Higher education was only found to be associated with an increased proportion of dense breasts in postmenopausal women (ORtrend = 1.08, 95%CI: 1.02-1.15). Premenopausal women who ever used oral hormone drug were less likely to have dense breasts, though the difference was marginally significant (OR = 0.54, P = 0.045). In postmenopausal women, we also found the proportion of dense breasts increased with age at menopause (ORtrend = 1.31, 95%CI: 1.21-1.43). CONCLUSIONS In Chinese women with average risk for breast cancer, we found MD was associated with age, BMI, menopausal status, lactation, and age at menopausal. This finding may help to understand the etiology of breast cancer and have implications for breast cancer prevention in China.
Collapse
Affiliation(s)
- Huijiao Yan
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Wenhui Ren
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Mengmeng Jia
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Peng Xue
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
| | - Zhifang Li
- Changzhi Medical College, Changzhi, 046000, Shanxi, China
| | - Shaokai Zhang
- Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, 450008, China
| | - Lichun He
- Mianyang Maternal & Child Health Care Hospital, Mianyang Children's Hospital, Mianyang, 621000, China
| | - Youlin Qiao
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
| |
Collapse
|
5
|
Louro J, Román M, Moshina N, Olstad CF, Larsen M, Sagstad S, Castells X, Hofvind S. Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway. Cancers (Basel) 2023; 15:4517. [PMID: 37760486 PMCID: PMC10526465 DOI: 10.3390/cancers15184517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 09/06/2023] [Accepted: 09/09/2023] [Indexed: 09/29/2023] Open
Abstract
BACKGROUND We aimed to develop and validate a model predicting breast cancer risk for women targeted by breast cancer screening. METHOD This retrospective cohort study included 57,411 women screened at least once in BreastScreen Norway during the period from 2007 to 2019. The prediction model included information about age, mammographic density, family history of breast cancer, body mass index, age at menarche, alcohol consumption, exercise, pregnancy, hormone replacement therapy, and benign breast disease. We calculated a 4-year absolute breast cancer risk estimates for women and in risk groups by quartiles. The Bootstrap resampling method was used for internal validation of the model (E/O ratio). The area under the curve (AUC) was estimated with a 95% confidence interval (CI). RESULTS The 4-year predicted risk of breast cancer ranged from 0.22-7.33%, while 95% of the population had a risk of 0.55-2.31%. The thresholds for the quartiles of the risk groups, with 25% of the population in each group, were 0.82%, 1.10%, and 1.47%. Overall, the model slightly overestimated the risk with an E/O ratio of 1.10 (95% CI: 1.09-1.11) and the AUC was 62.6% (95% CI: 60.5-65.0%). CONCLUSIONS This 4-year risk prediction model showed differences in the risk of breast cancer, supporting personalized screening for breast cancer in women aged 50-69 years.
Collapse
Affiliation(s)
- Javier Louro
- Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain; (J.L.); (M.R.); (X.C.)
- Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 48902 Barakaldo, Spain
| | - Marta Román
- Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain; (J.L.); (M.R.); (X.C.)
- Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 48902 Barakaldo, Spain
| | - Nataliia Moshina
- Section for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway; (N.M.); (C.F.O.); (M.L.); (S.S.)
| | - Camilla F. Olstad
- Section for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway; (N.M.); (C.F.O.); (M.L.); (S.S.)
| | - Marthe Larsen
- Section for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway; (N.M.); (C.F.O.); (M.L.); (S.S.)
| | - Silje Sagstad
- Section for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway; (N.M.); (C.F.O.); (M.L.); (S.S.)
| | - Xavier Castells
- Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain; (J.L.); (M.R.); (X.C.)
- Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), 48902 Barakaldo, Spain
| | - Solveig Hofvind
- Section for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway; (N.M.); (C.F.O.); (M.L.); (S.S.)
- Department of Health and Care Sciences, Faculty of Health Sciences, UiT, The Arctic University of Norway, 9037 Tromsø, Norway
| |
Collapse
|
6
|
Heine J, Fowler EEE, Berglund A, Schell MJ, Eschrich S. Techniques to produce and evaluate realistic multivariate synthetic data. Sci Rep 2023; 13:12266. [PMID: 37507387 PMCID: PMC10382509 DOI: 10.1038/s41598-023-38832-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 07/16/2023] [Indexed: 07/30/2023] Open
Abstract
Data modeling requires a sufficient sample size for reproducibility. A small sample size can inhibit model evaluation. A synthetic data generation technique addressing this small sample size problem is evaluated: from the space of arbitrarily distributed samples, a subgroup (class) has a latent multivariate normal characteristic; synthetic data can be generated from this class with univariate kernel density estimation (KDE); and synthetic samples are statistically like their respective samples. Three samples (n = 667) were investigated with 10 input variables (X). KDE was used to augment the sample size in X. Maps produced univariate normal variables in Y. Principal component analysis in Y produced uncorrelated variables in T, where the probability density functions were approximated as normal and characterized; synthetic data was generated with normally distributed univariate random variables in T. Reversing each step produced synthetic data in Y and X. All samples were approximately multivariate normal in Y, permitting the generation of synthetic data. Probability density function and covariance comparisons showed similarity between samples and synthetic samples. A class of samples has a latent normal characteristic. For such samples, this approach offers a solution to the small sample size problem. Further studies are required to understand this latent class.
Collapse
Affiliation(s)
- John Heine
- Cancer Epidemiology Department, Moffitt Cancer Center and Research Institute, 12902 Bruce B. Downs Blvd, Tampa, FL, 33612, USA.
| | - Erin E E Fowler
- Cancer Epidemiology Department, Moffitt Cancer Center and Research Institute, 12902 Bruce B. Downs Blvd, Tampa, FL, 33612, USA
| | - Anders Berglund
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, 12902 Bruce B. Downs Blvd, Tampa, FL, 33612, USA
| | - Michael J Schell
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, 12902 Bruce B. Downs Blvd, Tampa, FL, 33612, USA
| | - Steven Eschrich
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center and Research Institute, 12902 Bruce B. Downs Blvd, Tampa, FL, 33612, USA
| |
Collapse
|
7
|
Okunola HL, Shuryak I, Repin M, Wu HC, Santella RM, Terry MB, Turner HC, Brenner DJ. Improved prediction of breast cancer risk based on phenotypic DNA damage repair capacity in peripheral blood B cells. RESEARCH SQUARE 2023:rs.3.rs-3093360. [PMID: 37461559 PMCID: PMC10350237 DOI: 10.21203/rs.3.rs-3093360/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Background Standard Breast Cancer (BC) risk prediction models based only on epidemiologic factors generally have quite poor performance, and there have been a number of risk scores proposed to improve them, such as AI-based mammographic information, polygenic risk scores and pathogenic variants. Even with these additions BC risk prediction performance is still at best moderate. In that decreased DNA repair capacity (DRC) is a major risk factor for development of cancer, we investigated the potential to improve BC risk prediction models by including a measured phenotypic DRC assay. Methods Using blood samples from the Breast Cancer Family Registry we assessed the performance of phenotypic markers of DRC in 46 matched pairs of individuals, one from each pair with BC (with blood drawn before BC diagnosis) and the other from controls matched by age and time since blood draw. We assessed DRC in thawed cryopreserved peripheral blood mononuclear cells (PBMCs) by measuring γ-H2AX yields (a marker for DNA double-strand breaks) at multiple times from 1 to 20 hrs after a radiation challenge. The studies were performed using surface markers to discriminate between different PBMC subtypes. Results The parameter F res , the residual damage signal in PBMC B cells at 20 hrs post challenge, was the strongest predictor of breast cancer with an AUC (Area Under receiver-operator Curve) of 0.89 [95% Confidence Interval: 0.84-0.93] and a BC status prediction accuracy of 0.80. To illustrate the combined use of a phenotypic predictor with standard BC predictors, we combined F res in B cells with age at blood draw, and found that the combination resulted in significantly greater BC predictive power (AUC of 0.97 [95% CI: 0.94-0.99]), an increase of 13 percentage points over age alone. Conclusions If replicated in larger studies, these results suggest that inclusion of a fingerstick-based phenotypic DRC blood test has the potential to markedly improve BC risk prediction.
Collapse
Affiliation(s)
| | | | | | - Hui-Chen Wu
- Columbia University Mailman School of Public Health
| | | | | | | | | |
Collapse
|
8
|
Eriksson M, Czene K, Vachon C, Conant EF, Hall P. A Clinical Risk Model for Personalized Screening and Prevention of Breast Cancer. Cancers (Basel) 2023; 15:3246. [PMID: 37370856 DOI: 10.3390/cancers15123246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 06/10/2023] [Accepted: 06/18/2023] [Indexed: 06/29/2023] Open
Abstract
BACKGROUND Image-derived artificial intelligence (AI) risk models have shown promise in identifying high-risk women in the short term. The long-term performance of image-derived risk models expanded with clinical factors has not been investigated. METHODS We performed a case-cohort study of 8110 women aged 40-74 randomly selected from a Swedish mammography screening cohort initiated in 2010 together with 1661 incident BCs diagnosed before January 2022. The imaging-only AI risk model extracted mammographic features and age at screening. Additional lifestyle/familial risk factors were incorporated into the lifestyle/familial-expanded AI model. Absolute risks were calculated using the two models and the clinical Tyrer-Cuzick v8 model. Age-adjusted model performances were compared across the 10-year follow-up. RESULTS The AUCs of the lifestyle/familial-expanded AI risk model ranged from 0.75 (95%CI: 0.70-0.80) to 0.68 (95%CI: 0.66-0.69) 1-10 years after study entry. Corresponding AUCs were 0.72 (95%CI: 0.66-0.78) to 0.65 (95%CI: 0.63-0.66) for the imaging-only model and 0.62 (95%CI: 0.55-0.68) to 0.60 (95%CI: 0.58-0.61) for Tyrer-Cuzick v8. The increased performances were observed in multiple risk subgroups and cancer subtypes. Among the 5% of women at highest risk, the PPV was 5.8% using the lifestyle/familial-expanded model compared with 5.3% using the imaging-only model, p < 0.01, and 4.6% for Tyrer-Cuzick, p < 0.01. CONCLUSIONS The lifestyle/familial-expanded AI risk model showed higher performance for both long-term and short-term risk assessment compared with imaging-only and Tyrer-Cuzick models.
Collapse
Affiliation(s)
- Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 65 Stockholm, Sweden
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 65 Stockholm, Sweden
| | - Celine Vachon
- Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | - Emily F Conant
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 65 Stockholm, Sweden
- Department of Oncology, Södersjukhuset University Hospital, 118 83 Stockholm, Sweden
| |
Collapse
|
9
|
Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee C. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study. Radiology 2023; 307:e222733. [PMID: 37278627 PMCID: PMC10315521 DOI: 10.1148/radiol.222733] [Citation(s) in RCA: 19] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 04/05/2023] [Accepted: 04/18/2023] [Indexed: 06/07/2023]
Abstract
Background Although several clinical breast cancer risk models are used to guide screening and prevention, they have only moderate discrimination. Purpose To compare selected existing mammography artificial intelligence (AI) algorithms and the Breast Cancer Surveillance Consortium (BCSC) risk model for prediction of 5-year risk. Materials and Methods This retrospective case-cohort study included data in women with a negative screening mammographic examination (no visible evidence of cancer) in 2016, who were followed until 2021 at Kaiser Permanente Northern California. Women with prior breast cancer or a highly penetrant gene mutation were excluded. Of the 324 009 eligible women, a random subcohort was selected, regardless of cancer status, to which all additional patients with breast cancer were added. The index screening mammographic examination was used as input for five AI algorithms to generate continuous scores that were compared with the BCSC clinical risk score. Risk estimates for incident breast cancer 0 to 5 years after the initial mammographic examination were calculated using a time-dependent area under the receiver operating characteristic curve (AUC). Results The subcohort included 13 628 patients, of whom 193 had incident cancer. Incident cancers in eligible patients (additional 4391 of 324 009) were also included. For incident cancers at 0 to 5 years, the time-dependent AUC for BCSC was 0.61 (95% CI: 0.60, 0.62). AI algorithms had higher time-dependent AUCs than did BCSC, ranging from 0.63 to 0.67 (Bonferroni-adjusted P < .0016). Time-dependent AUCs for combined BCSC and AI models were slightly higher than AI alone (AI with BCSC time-dependent AUC range, 0.66-0.68; Bonferroni-adjusted P < .0016). Conclusion When using a negative screening examination, AI algorithms performed better than the BCSC risk model for predicting breast cancer risk at 0 to 5 years. Combined AI and BCSC models further improved prediction. © RSNA, 2023 Supplemental material is available for this article.
Collapse
Affiliation(s)
- Vignesh A. Arasu
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Laurel A. Habel
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Ninah S. Achacoso
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Diana S. M. Buist
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Jason B. Cord
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Laura J. Esserman
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Nola M. Hylton
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - M. Maria Glymour
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - John Kornak
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Lawrence H. Kushi
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Donald A. Lewis
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Vincent X. Liu
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Caitlin M. Lydon
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Diana L. Miglioretti
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Daniel A. Navarro
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Albert Pu
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Li Shen
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Weiva Sieh
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Hyo-Chun Yoon
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| | - Catherine Lee
- From the Division of Research, Kaiser Permanente Northern California,
2000 Broadway, Oakland, CA 94612 (V.A.A., L.A.H., N.S.A., L.H.K., V.X.L.,
C.M.L., C.L.); Department of Radiology, Kaiser Permanente Northern California,
Vallejo Medical Center, Vallejo, Calif (V.A.A.); Kaiser Permanente Washington
Health Research Institute, Seattle, Wash (D.S.M.B.); Department of Radiology,
Southern California Permanente Medical Group, Orange County, Irvine, Calif
(J.B.C.); Department of Surgery (L.J.E.), Department of Radiology and Biomedical
Imaging (N.M.H.), and Department of Epidemiology and Biostatistics (M.M.G.,
J.K.), University of California–San Francisco, San Francisco, Calif;
Department of Medical Imaging Technology and Informatics, Southern California
Permanente Medical Group, Pasadena, Calif (D.A.L.); Department of Biostatistics,
University of California–Davis, Davis, Calif (D.L.M.); The Technology
Group, The Permanente Medical Group, Oakland, Calif (D.A.N.); KP Information
Technology, Kaiser Foundation Health Plan Inc and Kaiser Foundation Hospitals,
Oakland, Calif (A.P.); Department of Artificial Intelligence and Human Health
and Nash Family Department of Neuroscience (L.S.) and Department of Population
Health Science and Policy, Department of Genetics and Genomic Sciences (W.S.),
Icahn School of Medicine at Mount Sinai, New York, NY; and Department of
Radiology, Hawaii Permanente Medical Group, Moanalua Medical Center, Honolulu,
Hawaii (H.C.Y.)
| |
Collapse
|
10
|
Eriksson M, Czene K, Vachon C, Conant EF, Hall P. Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer. J Clin Oncol 2023; 41:2536-2545. [PMID: 36930854 PMCID: PMC10414699 DOI: 10.1200/jco.22.01564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 02/09/2023] [Indexed: 03/19/2023] Open
Abstract
PURPOSE Image-derived artificial intelligence-based short-term risk models for breast cancer have shown high discriminatory performance compared with traditional lifestyle/familial-based risk models. The long-term performance of image-derived risk models has not been investigated. METHODS We performed a case-cohort study of 8,604 randomly selected women within a mammography screening cohort initiated in 2010 in Sweden for women age 40-74 years. Mammograms, age, lifestyle, and familial risk factors were collected at study entry. In all, 2,028 incident breast cancers were identified through register matching in May 2022 (206 incident breast cancers were found in the subcohort). The image-based model extracted mammographic features (density, microcalcifications, masses, and left-right breast asymmetries of these features) and age from study entry mammograms. The Tyrer-Cuzick v8 risk model incorporates self-reported lifestyle and familial risk factors and mammographic density to estimate risk. Absolute risks were estimated, and age-adjusted AUC model performances (aAUCs) were compared across the 10-year period. RESULTS The aAUCs of the image-based risk model ranged from 0.74 (95% CI, 0.70 to 0.78) to 0.65 (95% CI, 0.63 to 0.66) for breast cancers developed 1-10 years after study entry; the corresponding Tyrer-Cuzick aAUCs were 0.62 (95% CI, 0.56 to 0.67) to 0.60 (95% CI, 0.58 to 0.61). For symptomatic cancers, the aAUCs for the image-based model were ≥0.75 during the first 3 years. Women with high and low mammographic density showed similar aAUCs. Throughout the 10-year follow-up, 20% of all women with breast cancers were deemed high-risk at study entry by the image-based risk model compared with 7.1% using the lifestyle familial-based model (P < .01). CONCLUSION The image-based risk model outperformed the Tyrer-Cuzick v8 model for both short-term and long-term risk assessment and could be used to identify women who may benefit from supplemental screening and risk reduction strategies.
Collapse
Affiliation(s)
- Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | | | - Emily F. Conant
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Department of Oncology, Södersjukhuset University Hospital, Stockholm, Sweden
| |
Collapse
|
11
|
Ho PJ, Lim EH, Mohamed Ri NKB, Hartman M, Wong FY, Li J. Will Absolute Risk Estimation for Time to Next Screen Work for an Asian Mammography Screening Population? Cancers (Basel) 2023; 15:cancers15092559. [PMID: 37174025 PMCID: PMC10177032 DOI: 10.3390/cancers15092559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 04/26/2023] [Accepted: 04/27/2023] [Indexed: 05/15/2023] Open
Abstract
Personalized breast cancer risk profiling has the potential to promote shared decision-making and improve compliance with routine screening. We assessed the Gail model's performance in predicting the short-term (2- and 5-year) and the long-term (10- and 15-year) absolute risks in 28,234 asymptomatic Asian women. Absolute risks were calculated using different relative risk estimates and Breast cancer incidence and mortality rates (White, Asian-American, or the Singapore Asian population). Using linear models, we tested the association of absolute risk and age at breast cancer occurrence. Model discrimination was moderate (AUC range: 0.580-0.628). Calibration was better for longer-term prediction horizons (E/Olong-term ranges: 0.86-1.71; E/Oshort-term ranges:1.24-3.36). Subgroup analyses show that the model underestimates risk in women with breast cancer family history, positive recall status, and prior breast biopsy, and overestimates risk in underweight women. The Gail model absolute risk does not predict the age of breast cancer occurrence. Breast cancer risk prediction tools performed better with population-specific parameters. Two-year absolute risk estimation is attractive for breast cancer screening programs, but the models tested are not suitable for identifying Asian women at increased risk within this short interval.
Collapse
Affiliation(s)
- Peh Joo Ho
- Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore 138672, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 119228, Singapore
| | - Elaine Hsuen Lim
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore
| | - Nur Khaliesah Binte Mohamed Ri
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore
| | - Mikael Hartman
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 119228, Singapore
- Department of Surgery, University Surgical Cluster, National University Hospital, Singapore 119228, Singapore
| | - Fuh Yong Wong
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore
| | - Jingmei Li
- Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore 138672, Singapore
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore 119228, Singapore
| |
Collapse
|
12
|
Han Y, Zhu X, Hu Y, Yu C, Guo Y, Hang D, Pang Y, Pei P, Ma H, Sun D, Yang L, Chen Y, Du H, Yu M, Chen J, Chen Z, Huo D, Jin G, Lv J, Hu Z, Shen H, Li L. Electronic Health Record-Based Absolute Risk Prediction Model for Esophageal Cancer in the Chinese Population: Model Development and External Validation. JMIR Public Health Surveill 2023; 9:e43725. [PMID: 36781293 PMCID: PMC10132027 DOI: 10.2196/43725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 01/09/2023] [Accepted: 02/03/2023] [Indexed: 02/15/2023] Open
Abstract
BACKGROUND China has the largest burden of esophageal cancer (EC). Prediction models can be used to identify high-risk individuals for intensive lifestyle interventions and endoscopy screening. However, the current prediction models are limited by small sample size and a lack of external validation, and none of them can be embedded into the booming electronic health records (EHRs) in China. OBJECTIVE This study aims to develop and validate absolute risk prediction models for EC in the Chinese population. In particular, we assessed whether models that contain only EHR-available predictors performed well. METHODS A prospective cohort recruiting 510,145 participants free of cancer from both high EC-risk and low EC-risk areas in China was used to develop EC models. Another prospective cohort of 18,441 participants was used for validation. A flexible parametric model was used to develop a 10-year absolute risk model by considering the competing risks (full model). The full model was then abbreviated by keeping only EHR-available predictors. We internally and externally validated the models by using the area under the receiver operating characteristic curve (AUC) and calibration plots and compared them based on classification measures. RESULTS During a median of 11.1 years of follow-up, we observed 2550 EC incident cases. The models consisted of age, sex, regional EC-risk level (high-risk areas: 2 study regions; low-risk areas: 8 regions), education, family history of cancer (simple model), smoking, alcohol use, BMI (intermediate model), physical activity, hot tea consumption, and fresh fruit consumption (full model). The performance was only slightly compromised after the abbreviation. The simple and intermediate models showed good calibration and excellent discriminating ability with AUCs (95% CIs) of 0.822 (0.783-0.861) and 0.830 (0.792-0.867) in the external validation and 0.871 (0.858-0.884) and 0.879 (0.867-0.892) in the internal validation, respectively. CONCLUSIONS Three nested 10-year EC absolute risk prediction models for Chinese adults aged 30-79 years were developed and validated, which may be particularly useful for populations in low EC-risk areas. Even the simple model with only 5 predictors available from EHRs had excellent discrimination and good calibration, indicating its potential for broader use in tailored EC prevention. The simple and intermediate models have the potential to be widely used for both primary and secondary prevention of EC.
Collapse
Affiliation(s)
- Yuting Han
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Xia Zhu
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Yizhen Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Canqing Yu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
| | - Yu Guo
- Chinese Academy of Medical Sciences, Beijing, China
| | - Dong Hang
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Yuanjie Pang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Pei Pei
- Chinese Academy of Medical Sciences, Beijing, China
| | - Hongxia Ma
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Dianjianyi Sun
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
| | - Ling Yang
- Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Yiping Chen
- Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Huaidong Du
- Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Min Yu
- Zhejiang Center for Disease Control and Prevention, Hangzhou, China
| | - Junshi Chen
- China National Center for Food Safety Risk Assessment, Beijing, China
| | - Zhengming Chen
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Dezheng Huo
- Department of Public Health Sciences, The University of Chicago, Chicago, IL, United States
| | - Guangfu Jin
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Jun Lv
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
| | - Zhibin Hu
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Hongbing Shen
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, China International Cooperation Center for Environment and Human Health, Nanjing Medical University, Nanjing, China
| | - Liming Li
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China
| |
Collapse
|
13
|
Chotiyarnwong P, McCloskey EV, Harvey NC, Lorentzon M, Prieto-Alhambra D, Abrahamsen B, Adachi JD, Borgström F, Bruyere O, Carey JJ, Clark P, Cooper C, Curtis EM, Dennison E, Diaz-Curiel M, Dimai HP, Grigorie D, Hiligsmann M, Khashayar P, Lewiecki EM, Lips P, Lorenc RS, Ortolani S, Papaioannou A, Silverman S, Sosa M, Szulc P, Ward KA, Yoshimura N, Kanis JA. Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Arch Osteoporos 2022; 17:87. [PMID: 35763133 PMCID: PMC9239944 DOI: 10.1007/s11657-022-01117-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Accepted: 05/03/2022] [Indexed: 02/03/2023]
Abstract
The IOF Epidemiology and Quality of Life Working Group has reviewed the potential role of population screening for high hip fracture risk against well-established criteria. The report concludes that such an approach should strongly be considered in many health care systems to reduce the burden of hip fractures. INTRODUCTION The burden of long-term osteoporosis management falls on primary care in most healthcare systems. However, a wide and stable treatment gap exists in many such settings; most of which appears to be secondary to a lack of awareness of fracture risk. Screening is a public health measure for the purpose of identifying individuals who are likely to benefit from further investigations and/or treatment to reduce the risk of a disease or its complications. The purpose of this report was to review the evidence for a potential screening programme to identify postmenopausal women at increased risk of hip fracture. METHODS The approach took well-established criteria for the development of a screening program, adapted by the UK National Screening Committee, and sought the opinion of 20 members of the International Osteoporosis Foundation's Working Group on Epidemiology and Quality of Life as to whether each criterion was met (yes, partial or no). For each criterion, the evidence base was then reviewed and summarized. RESULTS AND CONCLUSION The report concludes that evidence supports the proposal that screening for high fracture risk in primary care should strongly be considered for incorporation into many health care systems to reduce the burden of fractures, particularly hip fractures. The key remaining hurdles to overcome are engagement with primary care healthcare professionals, and the implementation of systems that facilitate and maintain the screening program.
Collapse
Affiliation(s)
- P Chotiyarnwong
- Department of Oncology & Metabolism, Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK
- Department of Orthopaedic Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - E V McCloskey
- Department of Oncology & Metabolism, Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
- Centre for Metabolic Bone Diseases, Northern General Hospital, University of Sheffield, Herries Road, Sheffield, S5 7AU, UK.
| | - N C Harvey
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
| | - M Lorentzon
- University of Gothenburg, Gothenburg, Sweden
- Australian Catholic University, Melbourne, Australia
| | - D Prieto-Alhambra
- Oxford NIHR Biomedical Research Centre, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK
- GREMPAL (Grup de Recerca en Malalties Prevalents de L'Aparell Locomotor) Research Group, CIBERFes and Idiap Jordi Gol Primary Care Research Institute, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Gran Via de Les Corts Catalanes, 591 Atico, 08007, Barcelona, Spain
| | - B Abrahamsen
- Department of Clinical Research, Odense Patient Data Exploratory Network, University of Southern Denmark, Odense, Denmark
- Department of Medicine, Holbæk Hospital, Holbæk, Denmark
| | - J D Adachi
- Department of Medicine, Michael G DeGroote School of Medicine, St Joseph's Healthcare-McMaster University, Hamilton, ON, Canada
| | - F Borgström
- Quantify Research, Stockholm, Sweden
- Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden
| | - O Bruyere
- WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - J J Carey
- School of Medicine, National University of Ireland Galway, Galway, Ireland
- Department of Rheumatology, Galway University Hospitals, Galway, Ireland
| | - P Clark
- Clinical Epidemiology Unit of Hospital Infantil de México Federico Gómez-Faculty of Medicine, Universidad Nacional Autónoma de México, UNAM, Mexico City, Mexico
| | - C Cooper
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
| | - E M Curtis
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
| | - E Dennison
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
| | - M Diaz-Curiel
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - H P Dimai
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
| | - D Grigorie
- Carol Davila University of Medicine, Bucharest, Romania
- Department of Endocrinology & Bone Metabolism, National Institute of Endocrinology, Bucharest, Romania
| | - M Hiligsmann
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| | - P Khashayar
- Center for Microsystems Technology, Imec and Ghent University, 9050, Ghent, Belgium
| | - E M Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
| | - P Lips
- Department of Internal Medicine, Endocrine Section & Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - R S Lorenc
- Multidisciplinary Osteoporosis Forum, SOMED, Warsaw, Poland
| | - S Ortolani
- IRCCS Istituto Auxologico, UO Endocrinologia E Malattie del Metabolismo, Milano, Italy
| | - A Papaioannou
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- GERAS Centre for Aging Research, Hamilton, ON, Canada
| | - S Silverman
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - M Sosa
- Bone Metabolic Unit, University of Las Palmas de Gran Canaria, Hospital University Insular, Las Palmas, Gran Canaria, Spain
| | - P Szulc
- INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France
| | - K A Ward
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
| | - N Yoshimura
- Department of Preventive Medicine for Locomotive Organ Disorders, 22Nd Century Medical and Research Center, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - J A Kanis
- Centre for Metabolic Bone Diseases, Northern General Hospital, University of Sheffield, Herries Road, Sheffield, S5 7AU, UK
- Australian Catholic University, Melbourne, Australia
| |
Collapse
|
14
|
Eriksson M, Destounis S, Czene K, Zeiberg A, Day R, Conant EF, Schilling K, Hall P. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Sci Transl Med 2022; 14:eabn3971. [PMID: 35544593 DOI: 10.1126/scitranslmed.abn3971] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Screening with digital breast tomosynthesis (DBT) improves breast cancer detection and reduces false positives. However, currently, no breast cancer risk model takes advantage of the additional information generated by DBT imaging for breast cancer risk prediction. We developed and internally validated a DBT-based short-term risk model for predicting future late-stage and interval breast cancers after negative screening exams. We included the available 805 incident breast cancers and a random sample of 5173 healthy women matched on year of study entry in a nested case-control study from 154,200 multiethnic women, aged 35 to 74, attending DBT screening in the United States between 2014 and 2019. A relative risk model was trained using elastic net logistic regression and nested cross-validation to estimate risks for using imaging features and age. An absolute risk model was developed using derived risks and U.S. incidence and competing mortality rates. Absolute risks, discrimination performance, and risk stratification were estimated in the left-out validation set. The discrimination performance of 1-year risk was 0.82 (95% CI, 0.79 to 0.85) with good calibration (P = 0.7). Using the U.S. Preventive Service Task Force guidelines, 14% of the women were at high risk, 19.6 times higher compared to general risk. In this high-risk group, 76% of stage II and III cancers and 59% of stage 0 cancers were observed (P < 0.01). Using mammographic features generated from DBT screens, our image-based risk prediction model could guide radiologists in selecting women for clinical care, potentially leading to earlier detection and improved prognoses.
Collapse
Affiliation(s)
- Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska institutet, SE-171 77 Stockholm, Sweden
| | | | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska institutet, SE-171 77 Stockholm, Sweden
| | - Andrew Zeiberg
- Radiology Associates of Burlington County, Hainesport, NJ 08036, USA
| | - Robert Day
- Zwanger-Pesiri Radiology, Lindenhurst, NY 11757, USA
| | - Emily F Conant
- Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska institutet, SE-171 77 Stockholm, Sweden.,Department of Oncology, Södersjukhuset University Hospital, Stockholm SE-118 61, Sweden
| |
Collapse
|
15
|
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun 2022; 13:449. [PMID: 35105882 PMCID: PMC8807602 DOI: 10.1038/s41467-021-27918-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 12/02/2021] [Indexed: 02/07/2023] Open
Abstract
Genetic and non-genetic factors contribute to breast cancer development. An epigenome-based signature capturing these components in easily accessible samples could identify women at risk. Here, we analyse the DNA methylome in 2,818 cervical, 357 and 227 matched buccal and blood samples respectively, and 42 breast tissue samples from women with and without breast cancer. Utilising cervical liquid-based cytology samples, we develop the DNA methylation-based Women’s risk IDentification for Breast Cancer index (WID-BC-index) that identifies women with breast cancer with an AUROC (Area Under the Receiver Operator Characteristic) of 0.84 (95% CI: 0.80–0.88) and 0.81 (95% CI: 0.76–0.86) in internal and external validation sets, respectively. CpGs at progesterone receptor binding sites hypomethylated in normal breast tissue of women with breast cancer or in BRCA mutation carriers are also hypomethylated in cervical samples of women with poor prognostic breast cancer. Our data indicate that a systemic epigenetic programming defect is highly prevalent in women who develop breast cancer. Further studies validating the WID-BC-index may enable clinical implementation for monitoring breast cancer risk. Breast cancer is most commonly diagnosed via a needle biopsy. In this study, the authors show that cervical samples from women with breast cancer have a methylation signature different to that of healthy controls.
Collapse
|
16
|
Hurson AN, Pal Choudhury P, Gao C, Hüsing A, Eriksson M, Shi M, Jones ME, Evans DGR, Milne RL, Gaudet MM, Vachon CM, Chasman DI, Easton DF, Schmidt MK, Kraft P, Garcia-Closas M, Chatterjee N. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. Int J Epidemiol 2022; 50:1897-1911. [PMID: 34999890 PMCID: PMC8743128 DOI: 10.1093/ije/dyab036] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Accepted: 02/19/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Rigorous evaluation of the calibration and discrimination of breast-cancer risk-prediction models in prospective cohorts is critical for applications under clinical guidelines. We comprehensively evaluated an integrated model incorporating classical risk factors and a 313-variant polygenic risk score (PRS) to predict breast-cancer risk. METHODS Fifteen prospective cohorts from six countries with 239 340 women (7646 incident breast-cancer cases) of European ancestry aged 19-75 years were included. Calibration of 5-year risk was assessed by comparing expected and observed proportions of cases overall and within risk categories. Risk stratification for women of European ancestry aged 50-70 years in those countries was evaluated by the proportion of women and future cases crossing clinically relevant risk thresholds. RESULTS Among women <50 years old, the median (range) expected-to-observed ratio for the integrated model across 15 cohorts was 0.9 (0.7-1.0) overall and 0.9 (0.7-1.4) at the highest-risk decile; among women ≥50 years old, these were 1.0 (0.7-1.3) and 1.2 (0.7-1.6), respectively. The proportion of women identified above a 3% 5-year risk threshold (used for recommending risk-reducing medications in the USA) ranged from 7.0% in Germany (∼841 000 of 12 million) to 17.7% in the USA (∼5.3 of 30 million). At this threshold, 14.7% of US women were reclassified by adding the PRS to classical risk factors, with identification of 12.2% of additional future cases. CONCLUSION Integrating a 313-variant PRS with classical risk factors can improve the identification of European-ancestry women at elevated risk who could benefit from targeted risk-reducing strategies under current clinical guidelines.
Collapse
Affiliation(s)
- Amber N Hurson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Parichoy Pal Choudhury
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
- Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
| | - Chi Gao
- Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Anika Hüsing
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Mikael Eriksson
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Karolinska Univ Hospital, Stockholm, Sweden
| | - Min Shi
- Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA
| | - Michael E Jones
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
| | - D Gareth R Evans
- Division of Evolution and Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
- Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester NIHR Biomedical Research Centre, Manchester University Hospitals NHS, Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Mia M Gaudet
- Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA
| | - Celine M Vachon
- Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
| | - Daniel I Chasman
- Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Marjanka K Schmidt
- Division of Molecular Pathology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands
| | - Peter Kraft
- Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | | | - Nilanjan Chatterjee
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
- Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
| | | |
Collapse
|
17
|
Palmer JR, Zirpoli G, Bertrand KA, Battaglia T, Bernstein L, Ambrosone CB, Bandera EV, Troester MA, Rosenberg L, Pfeiffer RM, Trinquart L. A Validated Risk Prediction Model for Breast Cancer in US Black Women. J Clin Oncol 2021; 39:3866-3877. [PMID: 34623926 DOI: 10.1200/jco.21.01236] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PURPOSE Breast cancer risk prediction models are used to identify high-risk women for early detection, targeted interventions, and enrollment into prevention trials. We sought to develop and evaluate a risk prediction model for breast cancer in US Black women, suitable for use in primary care settings. METHODS Breast cancer relative risks and attributable risks were estimated using data from Black women in three US population-based case-control studies (3,468 breast cancer cases; 3,578 controls age 30-69 years) and combined with SEER age- and race-specific incidence rates, with incorporation of competing mortality, to develop an absolute risk model. The model was validated in prospective data among 51,798 participants of the Black Women's Health Study, including 1,515 who developed invasive breast cancer. A second risk prediction model was developed on the basis of estrogen receptor (ER)-specific relative risks and attributable risks. Model performance was assessed by calibration (expected/observed cases) and discriminatory accuracy (C-statistic). RESULTS The expected/observed ratio was 1.01 (95% CI, 0.95 to 1.07). Age-adjusted C-statistics were 0.58 (95% CI, 0.56 to 0.59) overall and 0.63 (95% CI, 0.58 to 0.68) among women younger than 40 years. These measures were almost identical in the model based on estrogen receptor-specific relative risks and attributable risks. CONCLUSION Discriminatory accuracy of the new model was similar to that of the most frequently used questionnaire-based breast cancer risk prediction models in White women, suggesting that effective risk stratification for Black women is now possible. This model may be especially valuable for risk stratification of young Black women, who are below the ages at which breast cancer screening is typically begun.
Collapse
Affiliation(s)
- Julie R Palmer
- Slone Epidemiology Center at Boston University, Boston, MA.,Boston University School of Medicine, Boston, MA
| | - Gary Zirpoli
- Slone Epidemiology Center at Boston University, Boston, MA
| | - Kimberly A Bertrand
- Slone Epidemiology Center at Boston University, Boston, MA.,Boston University School of Medicine, Boston, MA
| | | | | | | | | | - Melissa A Troester
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
| | - Lynn Rosenberg
- Slone Epidemiology Center at Boston University, Boston, MA
| | - Ruth M Pfeiffer
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD
| | | |
Collapse
|
18
|
Quantitative Breast Density in Contrast-Enhanced Mammography. J Clin Med 2021; 10:jcm10153309. [PMID: 34362092 PMCID: PMC8348046 DOI: 10.3390/jcm10153309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 07/20/2021] [Accepted: 07/22/2021] [Indexed: 11/16/2022] Open
Abstract
Contrast-enhanced mammography (CEM) demonstrates a potential role in personalized screening models, in particular for women at increased risk and women with dense breasts. In this study, volumetric breast density (VBD) measured in CEM images was compared with VBD obtained from digital mammography (DM) or tomosynthesis (DBT) images. A total of 150 women who underwent CEM between March 2019 and December 2020, having at least a DM/DBT study performed before/after CEM, were included. Low-energy CEM (LE-CEM) and DM/DBT images were processed with automatic software to obtain the VBD. VBDs from the paired datasets were compared by Wilcoxon tests. A multivariate regression model was applied to analyze the relationship between VBD differences and multiple independent variables certainly or potentially affecting VBD. Median VBD was comparable for LE-CEM and DM/DBT (12.73% vs. 12.39%), not evidencing any statistically significant difference (p = 0.5855). VBD differences between LE-CEM and DM were associated with significant differences of glandular volume, breast thickness, compression force and pressure, contact area, and nipple-to-posterior-edge distance, i.e., variables reflecting differences in breast positioning (coefficient of determination 0.6023; multiple correlation coefficient 0.7761). Volumetric breast density was obtained from low-energy contrast-enhanced spectral mammography and was not significantly different from volumetric breast density measured from standard mammograms.
Collapse
|
19
|
Han Y, Lv J, Yu C, Guo Y, Bian Z, Hu Y, Yang L, Chen Y, Du H, Zhao F, Wen W, Shu XO, Xiang Y, Gao YT, Zheng W, Guo H, Liang P, Chen J, Chen Z, Huo D, Li L. Development and external validation of a breast cancer absolute risk prediction model in Chinese population. Breast Cancer Res 2021; 23:62. [PMID: 34051827 PMCID: PMC8164768 DOI: 10.1186/s13058-021-01439-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Accepted: 05/17/2021] [Indexed: 01/06/2023] Open
Abstract
BACKGROUNDS In contrast to developed countries, breast cancer in China is characterized by a rapidly escalating incidence rate in the past two decades, lower survival rate, and vast geographic variation. However, there is no validated risk prediction model in China to aid early detection yet. METHODS A large nationwide prospective cohort, China Kadoorie Biobank (CKB), was used to evaluate relative and attributable risks of invasive breast cancer. A total of 300,824 women free of any prior cancer were recruited during 2004-2008 and followed up to Dec 31, 2016. Cox models were used to identify breast cancer risk factors and build a relative risk model. Absolute risks were calculated by incorporating national age- and residence-specific breast cancer incidence and non-breast cancer mortality rates. We used an independent large prospective cohort, Shanghai Women's Health Study (SWHS), with 73,203 women to externally validate the calibration and discriminating accuracy. RESULTS During a median of 10.2 years of follow-up in the CKB, 2287 cases were observed. The final model included age, residence area, education, BMI, height, family history of overall cancer, parity, and age at menarche. The model was well-calibrated in both the CKB and the SWHS, yielding expected/observed (E/O) ratios of 1.01 (95% confidence interval (CI), 0.94-1.09) and 0.94 (95% CI, 0.89-0.99), respectively. After eliminating the effect of age and residence, the model maintained moderate but comparable discriminating accuracy compared with those of some previous externally validated models. The adjusted areas under the receiver operating curve (AUC) were 0.634 (95% CI, 0.608-0.661) and 0.585 (95% CI, 0.564-0.605) in the CKB and the SWHS, respectively. CONCLUSIONS Based only on non-laboratory predictors, our model has a good calibration and moderate discriminating capacity. The model may serve as a useful tool to raise individuals' awareness and aid risk-stratified screening and prevention strategies.
Collapse
Affiliation(s)
- Yuting Han
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191 China
| | - Jun Lv
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191 China
- Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education, Beijing, China
- Peking University Institute of Environmental Medicine, Beijing, China
| | - Canqing Yu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191 China
| | - Yu Guo
- Chinese Academy of Medical Sciences, Beijing, China
| | - Zheng Bian
- Chinese Academy of Medical Sciences, Beijing, China
| | - Yizhen Hu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191 China
| | - Ling Yang
- Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK
- Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Yiping Chen
- Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK
- Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Huaidong Du
- Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK
- Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Fangyuan Zhao
- Department of Public Health Sciences, The University of Chicago, 5841 S. Maryland Ave., MC2000, Chicago, IL 60637 USA
| | - Wanqing Wen
- Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN USA
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN USA
| | - Yongbing Xiang
- State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yu-Tang Gao
- State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN USA
| | - Hong Guo
- Medical department, Liuyang Hospital of Traditional Chinese Medicine, Liuyang, China
| | - Peng Liang
- People’s Hospital of Liuyang, Liuyang, China
| | - Junshi Chen
- China National Center for Food Safety Risk Assessment, Beijing, China
| | - Zhengming Chen
- Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Dezheng Huo
- Department of Public Health Sciences, The University of Chicago, 5841 S. Maryland Ave., MC2000, Chicago, IL 60637 USA
| | - Liming Li
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191 China
| |
Collapse
|
20
|
Moskowitz CS, Ronckers CM, Chou JF, Smith SA, Friedman DN, Barnea D, Kok JL, de Vries S, Wolden SL, Henderson TO, van der Pal HJH, Kremer LCM, Neglia JP, Turcotte LM, Howell RM, Arnold MA, Schaapveld M, Aleman B, Janus C, Versluys B, Leisenring W, Sklar CA, Begg CB, Pike MC, Armstrong GT, Robison LL, van Leeuwen FE, Oeffinger KC. Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. J Clin Oncol 2021; 39:3012-3021. [PMID: 34048292 DOI: 10.1200/jco.20.02244] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Women treated with chest radiation for childhood cancer have one of the highest risks of breast cancer. Models producing personalized breast cancer risk estimates applicable to this population do not exist. We sought to develop and validate a breast cancer risk prediction model for childhood cancer survivors treated with chest radiation incorporating treatment-related factors, family history, and reproductive factors. METHODS Analyses were based on multinational cohorts of female 5-year survivors of cancer diagnosed younger than age 21 years and treated with chest radiation. Model derivation was based on 1,120 participants in the Childhood Cancer Survivor Study diagnosed between 1970 and 1986, with median attained age 42 years (range 20-64) and 242 with breast cancer. Model validation included 1,027 participants from three cohorts, with median age 32 years (range 20-66) and 105 with breast cancer. RESULTS The model included current age, chest radiation field, whether chest radiation was delivered within 1 year of menarche, anthracycline exposure, age at menopause, and history of a first-degree relative with breast cancer. Ten-year risk estimates ranged from 2% to 23% for 30-year-old women (area under the curve, 0.63; 95% CI, 0.50 to 0.73) and from 5% to 34% for 40-year-old women (area under the curve, 0.67; 95% CI, 0.54 to 0.84). The highest risks were among premenopausal women older than age 40 years treated with mantle field radiation within a year of menarche who had a first-degree relative with breast cancer. It showed good calibration with an expected-to-observed ratio of the number of breast cancers of 0.92 (95% CI, 0.74 to 1.16). CONCLUSION Breast cancer risk varies among childhood cancer survivors treated with chest radiation. Accurate risk prediction may aid in refining surveillance, counseling, and preventive strategies in this population.
Collapse
Affiliation(s)
| | - Cécile M Ronckers
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Brandenburg Medical School Theodor Fontane, Neuruppin, Germany
| | - Joanne F Chou
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - Susan A Smith
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Dana Barnea
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Judith L Kok
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | | | | | - Tara O Henderson
- University of Chicago Medicine Comer Children's Hospital, Chicago, IL
| | | | | | - Joseph P Neglia
- University of Minnesota Masonic Cancer Center, Minneapolis, MN
| | | | | | | | | | - Berthe Aleman
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | | | - Birgitta Versluys
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | | | | | - Colin B Begg
- Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | |
Collapse
|
21
|
Quante AS, Hüsing A, Chang-Claude J, Kiechle M, Kaaks R, Pfeiffer RM. Estimating the Breast Cancer Burden in Germany and Implications for Risk-based Screening. Cancer Prev Res (Phila) 2021; 14:627-634. [PMID: 34162683 DOI: 10.1158/1940-6207.capr-20-0437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 11/26/2020] [Accepted: 03/04/2021] [Indexed: 12/24/2022]
Abstract
In Germany, it is currently recommended that women start mammographic breast cancer screening at age 50. However, recently updated guidelines state that for women younger than 50 and older than 70 years of age, screening decisions should be based on individual risk. International clinical guidelines recommend starting screening when a woman's 5-year risk of breast cancer exceeds 1.7%. We thus compared the performance of the current age-based screening practice with an alternative risk-adapted approach using data from a German population representative survey. We found that 10,498,000 German women ages 50-69 years are eligible for mammographic screening based on age alone. Applying the 5-year risk threshold of 1.7% to individual breast cancer risk estimated from a model that considers a woman's reproductive and personal characteristics, 39,000 German women ages 40-49 years would additionally be eligible. Among those women, the number needed to screen to detect one breast cancer case, NNS, was 282, which was close to the NNS = 292 among all 50- to 69-year-old women. In contrast, NNS = 703 for the 113,000 German women ages 50-69 years old with 5-year breast cancer risk <0.8%, the median 5-year breast cancer risk for German women ages 45-49 years, which we used as a low-risk threshold. For these low-risk women, longer screening intervals might be considered to avoid unnecessary diagnostic procedures. In conclusion, we show that risk-adapted mammographic screening could benefit German women ages 40-49 years who are at elevated breast cancer risk and reduce cost and burden among low-risk women ages 50-69 years. PREVENTION RELEVANCE: We show that a risk-based approach to mammography screening for German women can help detect breast cancer in women ages 40-49 years with increased risk and reduce screening costs and burdens for low-risk women ages 50-69 years. However, before recommending a particular implementation of a risk-based mammographic screening approach, further investigations of models and thresholds used are needed.
Collapse
Affiliation(s)
- Anne S Quante
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. .,Institute of Human Genetics, University Medical Centre Freiburg, Freiburg, Germany
| | - Anika Hüsing
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Institute of Medical Informatics, Biometry and Epidemiology, Universitätsklinikum Essen, Essen, Germany
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Marion Kiechle
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Ruth M Pfeiffer
- Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
| |
Collapse
|
22
|
Buist DSM. Factors to Consider in Developing Breast Cancer Risk Models to Implement into Clinical Care. CURR EPIDEMIOL REP 2021; 7:113-116. [PMID: 33552842 DOI: 10.1007/s40471-020-00230-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Purpose of the review This article outlines considerations for individuals interested in developing and implementing breast cancer risk models and has relevance for individuals developing risk-models with the goal of implementing them into health systems. Recent findings There has been increased focus on developing risk models for clinical use-often with less attention model implementation. Epidemiologists developing risk-models must think through model outcomes including stakeholder needs, time horizons, terminology and reference groups and clarity on what actionable steps are for health systems, providers and patients following its implementation. Summary Model performance needs to be evaluated relative to complexity of the model to be implemented-not just from the risk-prediction perspective, but also from the burden on patients, providers and systems for the amount and frequency of required data collection and with clear actionable steps to be taken with the information collected.
Collapse
Affiliation(s)
- Diana S M Buist
- Kaiser Permanente Washington Health Research Institute, Seattle WA
| |
Collapse
|
23
|
Kable JA, Coles CD, Jones KL, Yevtushok L, Kulikovsky Y, Zymak-Zakutnya N, Dubchak I, Akhmedzhanova D, Wertelecki W, Chambers CD. Infant Cardiac Orienting Responses Predict Later FASD in the Preschool Period. Alcohol Clin Exp Res 2021; 45:386-394. [PMID: 33277942 PMCID: PMC7887046 DOI: 10.1111/acer.14525] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Accepted: 11/19/2020] [Indexed: 01/01/2023]
Abstract
BACKGROUND Prenatal alcohol exposure (PAE) has been identified as one of the leading preventable causes of developmental disabilities, but early identification of those impacted has been challenging. This study evaluated the use of infant cardiac orienting responses (CORs), which assess neurophysiological encoding of environmental events and are sensitive to the impact of PAE, to predict later fetal alcohol spectrum disorder (FASD) status. METHODS Mother-infant dyads from Ukraine were recruited during pregnancy based on the mother's use of alcohol. Participants (n = 120) were then seen at 6 and 12 months when CORs were collected and in the preschool period when they were categorized as having (i) fetal alcohol syndrome (FAS), (ii) partial FAS (pFAS), (iii) alcohol-related neurodevelopmental disorder (ARND), (iv) PAE and no diagnosis, or (v) no PAE and no diagnosis. To assess CORs, stimuli (auditory tones and pictures) were presented using a fixed-trial habituation/dishabituation paradigm. Heart rate (HR) responses were aggregated across the first 3 habituation and dishabituation trials and converted to z-scores relative to the sample's mean response at each second by stimuli. Z-scores greater than 1 were then counted by condition (habituation or dishabituation) to compute a total risk index. RESULTS Significant group differences were found on total deviation scores of the CORs elicited from visual but not auditory stimuli. Those categorized as pFAS/FAS had significantly higher total deviation scores than did those categorized as ARND or as having no alcohol-related diagnosis with or without a history of PAE. Receiver operating characteristic curve analysis of the visual response yielded an area under the curve value of 0.765 for predicting to pFAS/FAS status. CONCLUSIONS A score reflecting total deviation from typical HR during CORs elicited using visual stimuli in infancy may be useful in identifying individuals who need early intervention as a result of their PAE.
Collapse
Affiliation(s)
- Julie A Kable
- From the Department of Psychiatry and Behavioral Science (JAK, CDC), Emory University School of Medicine, Atlanta, Georgia, USA
- Department of and Pediatrics (JAK, CDC), Emory University School of Medicine, Atlanta, Georgia, USA
| | - Claire D Coles
- From the Department of Psychiatry and Behavioral Science (JAK, CDC), Emory University School of Medicine, Atlanta, Georgia, USA
- Department of and Pediatrics (JAK, CDC), Emory University School of Medicine, Atlanta, Georgia, USA
| | - Kenneth L Jones
- Department of Pediatrics (KLJ, WW, ChDC), University of California San Diego, La Jolla, California, USA
- Department of Family Medicine and Public Health (KLJ, ChDC), University of California San Diego, La Jolla, California, USA
| | - Lyubov Yevtushok
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
- Rivne Regional Medical Diagnostic Center (LY, YK), Rivne, Ukraine
- Lviv National Medical University (LY), Lviv, Ukraine
| | - Yaroslav Kulikovsky
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
- Rivne Regional Medical Diagnostic Center (LY, YK), Rivne, Ukraine
| | - Natalya Zymak-Zakutnya
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
- Khmelnytsky Perinatal Center (NZ-Z, ID, DA), Khmelnytsky, Ukraine
| | - Iryna Dubchak
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
- Khmelnytsky Perinatal Center (NZ-Z, ID, DA), Khmelnytsky, Ukraine
| | - Diana Akhmedzhanova
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
- Khmelnytsky Perinatal Center (NZ-Z, ID, DA), Khmelnytsky, Ukraine
| | - Wladimir Wertelecki
- Department of Pediatrics (KLJ, WW, ChDC), University of California San Diego, La Jolla, California, USA
- OMNI-Net Ukraine Birth Defects Program (LY, YK, NZ-Z, ID, DA, WW), Rivne, Ukraine
| | - Christina D Chambers
- Department of Pediatrics (KLJ, WW, ChDC), University of California San Diego, La Jolla, California, USA
- Department of Family Medicine and Public Health (KLJ, ChDC), University of California San Diego, La Jolla, California, USA
| |
Collapse
|
24
|
Gail MH. Choosing Breast Cancer Risk Models: Importance of Independent Validation. J Natl Cancer Inst 2020; 112:433-435. [PMID: 31556449 DOI: 10.1093/jnci/djz180] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 09/04/2019] [Indexed: 12/23/2022] Open
Affiliation(s)
- Mitchel H Gail
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| |
Collapse
|
25
|
Pfeiffer RM, Rotman Y, O’Brien TR. Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score? Hepatology 2020; 72:794-796. [PMID: 32506469 PMCID: PMC8900528 DOI: 10.1002/hep.31413] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 05/28/2020] [Accepted: 05/30/2020] [Indexed: 01/06/2023]
Affiliation(s)
- Ruth M. Pfeiffer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Yaron Rotman
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
| | - Thomas R. O’Brien
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD
| |
Collapse
|
26
|
Gail MH, Pee D. Robustness of risk-based allocation of resources for disease prevention. Stat Methods Med Res 2020; 29:3511-3524. [PMID: 32552454 DOI: 10.1177/0962280220930055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Risk models for disease incidence can be useful for allocating resources for disease prevention if risk assessment is not too expensive. Assume there is a preventive intervention that should be given to everyone, but preventive resources are limited. We optimize risk-based prevention strategies and investigate robustness to modeling assumptions. The optimal strategy defines the proportion of the population to be given risk assessment and who should be offered intervention. The optimal strategy depends on the ratio of available resources to resources needed to intervene on everyone, and on the ratio of the costs of risk assessment to intervention. Risk assessment is not recommended if it is too expensive. Preventive efficiency decreases with decreasing compliance to risk assessment or intervention. Risk measurement error has little effect nor does misspecification of the risk distribution. Ignoring population substructure has small effects on optimal prevention strategy but can lead to modest over- or under-spending. We give conditions under which ignoring population substructure has no effect on optimal strategy. Thus, a simple one-population model offers robust guidance on prevention strategy but requires data on available resources, costs of risk assessment and intervention, population risk distribution, and probabilities of acceptance of risk assessment and intervention.
Collapse
Affiliation(s)
- Mitchell H Gail
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - David Pee
- Rockville Office, Information Management Services, Inc., Rockville, MD, USA
| |
Collapse
|
27
|
Performance of BCRAT in high-risk patients with breast cancer. Lancet Oncol 2020; 20:e285. [PMID: 31162092 DOI: 10.1016/s1470-2045(19)30301-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 03/20/2019] [Indexed: 12/16/2022]
|
28
|
Harkness EF, Astley SM, Evans D. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol 2020; 65:3-17. [DOI: 10.1016/j.bpobgyn.2019.11.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 10/14/2019] [Accepted: 11/10/2019] [Indexed: 10/25/2022]
|
29
|
|
30
|
Megjhani M, Kaffashi F, Terilli K, Alkhachroum A, Esmaeili B, Doyle KW, Murthy S, Velazquez AG, Connolly ES, Roh DJ, Agarwal S, Loparo KA, Claassen J, Boehme A, Park S. Heart Rate Variability as a Biomarker of Neurocardiogenic Injury After Subarachnoid Hemorrhage. Neurocrit Care 2020; 32:162-171. [PMID: 31093884 PMCID: PMC6856427 DOI: 10.1007/s12028-019-00734-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND The objective of this study was to examine whether heart rate variability (HRV) measures can be used to detect neurocardiogenic injury (NCI). METHODS Three hundred and twenty-six consecutive admissions with aneurysmal subarachnoid hemorrhage (SAH) met criteria for the study. Of 326 subjects, 56 (17.2%) developed NCI which we defined by wall motion abnormality with ventricular dysfunction on transthoracic echocardiogram or cardiac troponin-I > 0.3 ng/mL without electrocardiogram evidence of coronary artery insufficiency. HRV measures (in time and frequency domains, as well as nonlinear technique of detrended fluctuation analysis) were calculated over the first 48 h. We applied longitudinal multilevel linear regression to characterize the relationship of HRV measures with NCI and examine between-group differences at baseline and over time. RESULTS There was decreased vagal activity in NCI subjects with a between-group difference in low/high frequency ratio (β 3.42, SE 0.92, p = 0.0002), with sympathovagal balance in favor of sympathetic nervous activity. All time-domain measures were decreased in SAH subjects with NCI. An ensemble machine learning approach translated these measures into a classification tool that demonstrated good discrimination using the area under the receiver operating characteristic curve (AUROC 0.82), the area under precision recall curve (AUPRC 0.75), and a correct classification rate of 0.81. CONCLUSIONS HRV measures are significantly associated with our label of NCI and a machine learning approach using features derived from HRV measures can classify SAH patients that develop NCI.
Collapse
Affiliation(s)
- Murad Megjhani
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Farhad Kaffashi
- Case School of Engineering, Case Western Reserve University, Cleveland, USA
| | - Kalijah Terilli
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Ayham Alkhachroum
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Behnaz Esmaeili
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Kevin William Doyle
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Santosh Murthy
- Department of Neurology, Weill Cornell Medical College, New York, USA
| | - Angela G Velazquez
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - E Sander Connolly
- Department of Neurosurgery, Columbia University Irving Medical Center, New York, USA
| | - David Jinou Roh
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Sachin Agarwal
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Ken A Loparo
- Case School of Engineering, Case Western Reserve University, Cleveland, USA
| | - Jan Claassen
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Amelia Boehme
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA
| | - Soojin Park
- Department of Neurology, Columbia University Irving Medical Center, 177 Fort Washington Ave, 8 Milstein-300 Center, New York, NY, 10032, USA.
| |
Collapse
|
31
|
Risk prediction of cervical abnormalities: The value of sociodemographic and lifestyle factors in addition to HPV status. Prev Med 2020; 130:105927. [PMID: 31756350 DOI: 10.1016/j.ypmed.2019.105927] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Revised: 10/21/2019] [Accepted: 11/18/2019] [Indexed: 01/07/2023]
Abstract
High-risk human papillomavirus (hrHPV) assessment as a primary screening test improves sensitivity but decreases specificity. Determining risk for cervical abnormalities and adapting policy accordingly may improve the balance between screening benefits and harms. Our aim is to assess the value of factors other than HPV in prediction of cervical abnormalities. Data from a Dutch prospective cohort were used. Women aged 18-29 years, not yet eligible for screening, were included in 2007. Data collection consisted of a questionnaire and a cervicovaginal self-sample. Linkage with PALGA (pathology database) was performed in 2017. The analyses included 1483 women. The full model, including sociodemographic and lifestyle factors, was compared to the null model, including baseline HPV only. The outcome of interest was cervical intraepithelial neoplasia 2 or worse (CIN2+). There were 86 women with CIN2+. Baseline hrHPV status was an important predictor (OR = 5.20, 95%CI = 3.27-8.27). The area under the ROC curve (AUC) of the null model was 0.67 (95%CI = 0.61-0.72). The full model had a slightly higher AUC of 0.73 (95%CI = 0.67-0.79). Bootstrap validation indicated that overfitting was present. This exploratory study has confirmed that a single hrHPV measurement is a strong predictor of cervical abnormalities, and additional risk factors in young women appeared to have limited added value. However, prediction based on hrHPV only does leave room for improvement. Future studies should therefore focus on women in the screening age range and search for other predictors to further enhance risk prediction. Adapting policy based on risk may eventually help optimise screening performance.
Collapse
|
32
|
Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PDP, Shah M, Siesling S, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RAEM, van den Broek AJ, van Deurzen CHM, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK. Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Res 2019; 21:144. [PMID: 31847907 PMCID: PMC6918633 DOI: 10.1186/s13058-019-1221-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 10/29/2019] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making. METHODS We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility. RESULTS In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years, 0.52-0.74; at 10 years, 0.53-0.72). Calibration-in-the-large was -0.13 (95% PI: -1.62-1.37), and the calibration slope was 0.90 (95% PI: 0.73-1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52-0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers. CONCLUSIONS We developed a reasonably calibrated model to predict the risk of CBC in women of European-descent; however, prediction accuracy was moderate. Our model shows potential for improved risk counseling, but decision-making regarding contralateral preventive mastectomy, especially in the general breast cancer population where limited information of the mutation status in BRCA1/2 is available, remains challenging.
Collapse
Affiliation(s)
- Daniele Giardiello
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
| | - Ewout W Steyerberg
- Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- Department of Public Health, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Michael Hauptmann
- Institute of Biometry and Registry Research, Brandenburg Medical School, Neuruppin, Germany
- Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Muriel A Adank
- The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands
| | - Delal Akdeniz
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Carl Blomqvist
- Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- Department of Oncology, Örebro University Hospital, Örebro, Sweden
| | - Stig E Bojesen
- Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Manjeet K Bolla
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Mariël Brinkhuis
- East-Netherlands, Laboratory for Pathology, Hengelo, The Netherlands
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Kamila Czene
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Peter Devilee
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - Alison M Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Diana M Eccles
- Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Peter A Fasching
- Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Jonine Figueroa
- Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK
- Cancer Research UK Edinburgh Centre, Edinburgh, UK
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Henrik Flyger
- Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
| | - Montserrat García-Closas
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Lothar Haeberle
- Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - Christopher A Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Per Hall
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Oncology, Södersjukhuset, Stockholm, Sweden
| | - Ute Hamann
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - John L Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Agnes Jager
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Anna Jakubowska
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland
| | - Audrey Jung
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Renske Keeman
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Iris Kramer
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Diether Lambrechts
- VIB Center for Cancer Biology, VIB, Leuven, Belgium
- Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium
| | - Loic Le Marchand
- University of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA
| | - Annika Lindblom
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden
| | - Jan Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Mehdi Manoochehri
- Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Luigi Mariani
- Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Heli Nevanlinna
- Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
| | - Hester S A Oldenburg
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Saskia Pelders
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Mitul Shah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Sabine Siesling
- Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
| | - Vincent T H B M Smit
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - Melissa C Southey
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
- Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia
| | | | - Rob A E M Tollenaar
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
| | - Alexandra J van den Broek
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | | | - Flora E van Leeuwen
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands
| | - Chantal van Ongeval
- Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | - Laura J Van't Veer
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Qin Wang
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Camilla Wendt
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
| | | | - Maartje J Hooning
- Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Marjanka K Schmidt
- Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
| |
Collapse
|
33
|
Affiliation(s)
- Lydia E Pace
- Division of Women's Health, Brigham and Women's Hospital, Boston, Massachusetts
- Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Nancy L Keating
- Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
34
|
Fowler EE, Smallwood A, Khan N, Miltich C, Drukteinis J, Sellers TA, Heine J. Calibrated Breast Density Measurements. Acad Radiol 2019; 26:1181-1190. [PMID: 30545682 PMCID: PMC6557684 DOI: 10.1016/j.acra.2018.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 09/28/2018] [Accepted: 10/04/2018] [Indexed: 11/20/2022]
Abstract
RATIONALE AND OBJECTIVES Mammographic density is an important risk factor for breast cancer, but translation to the clinic requires assurance that prior work based on mammography is applicable to current technologies. The purpose of this work is to evaluate whether a calibration methodology developed previously produces breast density metrics predictive of breast cancer risk when applied to a case-control study. MATERIALS AND METHODS A matched case control study (n = 319 pairs) was used to evaluate two calibrated measures of breast density. Two-dimensional mammograms were acquired from six Hologic mammography units: three conventional Selenia two-dimensional full-field digital mammography systems and three Dimensions digital breast tomosynthesis systems. We evaluated the capability of two calibrated breast density measures to quantify breast cancer risk: the mean (PGm) and standard deviation (PGsd) of the calibrated pixels. Matching variables included age, hormone replacement therapy usage/duration, screening history, and mammography unit. Calibrated measures were compared to the percentage of breast density (PD) determined with the operator-assisted Cumulus method. Conditional logistic regression was used to generate odds ratios (ORs) from continuous and quartile (Q) models with 95% confidence intervals. The area under the receiver operating characteristic curve (Az) was also used as a comparison metric. Both univariate models and models adjusted for body mass index and ethnicity were evaluated. RESULTS In adjusted models, both PGsd and PD were statistically significantly associated with breast cancer with similar Az of 0.61-0.62. The corresponding ORs and confidence intervals were also similar. For PGsd, the OR was 1.34 (1.09, 1.66) for the continuous measure and 1.83 (1.11, 3.02), 2.19 (1.28, 3.73), and 2.20 (1.26, 3.85) for Q2-Q4. For PD, the OR was 1.43 (1.16, 1.76) for the continuous measure and 0.84 (0.52, 1.38), 1.96 (1.19, 3.23), and 2.27 (1.29, 4.00) for Q2-Q4. The results for PGm were slightly attenuated and not statistically significant. The OR was 1.22 (0.99, 1.51) with Az = 0.60 for the continuous measure and 1.24 (0.78, 1.97), 0.98 (0.60, 1.61), and 1.26, (0.77, 2.07) for Q2-Q4 with Az = 0.60. CONCLUSION The calibrated PGsd measure provided significant associations with breast cancer comparable to those given by PD. The calibrated PGm performed slightly worse. These findings indicate that the calibration approach developed previously replicates under more general conditions.
Collapse
Affiliation(s)
| | | | | | | | - Jennifer Drukteinis
- Moffitt Cancer Center & Research Institute, 12901 Bruce B. Downs Blvd, Tampa FL, 33612 (MCC)
| | | | - John Heine
- Corresponding Author information: John Heine, PhD, Moffitt Cancer Center & Research Institute, 12901 Bruce B, Downs Blvd, Mail Stop: Can/Cont, Tampa, FL 33612, Phone: 813-745-6719
| |
Collapse
|
35
|
Tice JA, Bissell MCS, Miglioretti DL, Gard CC, Rauscher GH, Dabbous FM, Kerlikowske K. Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat 2019; 175:519-523. [PMID: 30796654 DOI: 10.1007/s10549-019-05167-2] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Accepted: 02/14/2019] [Indexed: 11/29/2022]
Abstract
PURPOSE In order to use a breast cancer prediction model in clinical practice to guide screening and prevention, it must be well calibrated and validated in samples independent from the one used for development. We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. METHODS The BCSC model combines breast density with other risk factors to estimate a woman's 5- and 10-year risk of invasive breast cancer. We validated the model in an independent cohort of 252,997 women in the Chicago area. We evaluated calibration using the ratio of expected to observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). RESULTS In an independent cohort of 252,997 women (median age 50 years, 26% non-Hispanic Black), the BCSC model was well calibrated (E/O = 0.94, 95% confidence interval [CI] 0.90-0.98), but underestimated the incidence of invasive breast cancer in younger women and in women with low mammographic density. The AUROC was 0.633, similar to that observed in prior validation studies. CONCLUSIONS The BCSC model is a well-validated risk assessment tool for breast cancer that may be particularly useful when assessing the utility of supplemental screening in women with dense breasts.
Collapse
Affiliation(s)
- Jeffrey A Tice
- Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, 1545 Divisadero Street, Suite 309, San Francisco, CA, 94143-0320, USA.
| | - Michael C S Bissell
- Department of Public Health Sciences, University of California, Davis, Davis, CA, USA
| | - Diana L Miglioretti
- Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.,Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
| | - Charlotte C Gard
- Department of Economics, Applied Statistics, and International Business, New Mexico State University, Las Cruces, NM, USA
| | - Garth H Rauscher
- Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA
| | | | - Karla Kerlikowske
- General Internal Medicine Section, Department of Veteran Affairs and Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
| |
Collapse
|
36
|
Friedenreich CM, McTiernan A. Combining Variables for Cancer Risk Estimation: Is the Sum Better than the Parts? Cancer Prev Res (Phila) 2018; 11:313-316. [PMID: 29776914 DOI: 10.1158/1940-6207.capr-18-0102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 03/29/2018] [Accepted: 03/30/2018] [Indexed: 11/16/2022]
Abstract
Examining joint exposures of modifiable breast cancer risk factors may provide advantages over individual exposure-disease association analyses. Using the Healthy Lifestyle Index, Arthur and colleagues analyzed the joint impacts of diet, alcohol, smoking, physical activity, and obesity on breast cancer risk, and subtypes, in postmenopausal women enrolled in the Women's Health Initiative. The analysis provides data for population-attributable risk estimations and future prevention trials to target multiple risk factors. The public health messages for the individual risk factors remain unchanged, however, and it is still not clear whether improving one risk factor can counteract the adverse effects of another. Cancer Prev Res; 11(6); 313-6. ©2018 AACRSee related article by Arthur et al., p. 317.
Collapse
Affiliation(s)
- Christine M Friedenreich
- Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada. .,Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Anne McTiernan
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.,Departments of Epidemiology and Medicine (Geriatrics), Schools of Public Health and Medicine, University of Washington, Seattle, Washington
| |
Collapse
|